(Q36658915)

15 August 2017

1 reference

title

Clinical application of biochemical markers of bone turnover (English)

1 reference

15 August 2017

Markus J Seibel

1

1 reference

15 August 2017

publication date

1 August 2006

1 reference

Arquivos Brasileiros de Endocrinologia e Metabologia

15 August 2017

published in

1 reference

15 August 2017

volume

50

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

603-620

1 reference

Endocrine regulation of bone turnover in men.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled,

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Changes in bone density and turnover after alendronate or estrogen withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Serum osteocalcin and fracture susceptibility in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Biochemical markers of bone turnover reflect femoral bone loss in elderly women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Effect of age-related chronic immobility on markers of bone turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

High bone turnover is an independent predictor of mortality in the frail elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Calcium metabolism in the frail elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Effects of low-dose prednisone on bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Assessment of age and risk factors on bone density and bone turnover in healthy premenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Relationship of bone turnover to bone density and fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Screening procedure for women at risk of developing postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Can biochemical markers predict bone loss at the hip and spine?: a 4-year prospective study of 141 early postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Vitamin K counteracts the effect of warfarin in liver but not in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Daily and cyclic parathyroid hormone in women receiving alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Exploring the Relationship Between Surrogates and Clinical Outcomes: Analysis of Individual Patient Data vs. Meta-regression on Group-Level Summary Statistics

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Compliance with drug therapies for the treatment and prevention of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Biochemical markers of bone metabolism after short and long time ethanol withdrawal in alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH‐deficient adults: the effects on renal phosphate handling, bone turnover and bone mineral mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Clinical use of markers of bone turnover in metastatic bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400006

10.1590/S0004-27302006000400006

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference